Kronos Bio, Inc., a San Mateo, Calif.- and Cambridge, Mass.-based clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics, raised approximately $155m of convertible notes.
$148 million in funding were received to date and the remaining $7 million is to be funded by mid-September pursuant to binding commitments.
The round was led by Perceptive Advisors and included funds and accounts managed by BlackRock, Inc., funds affiliated with Casdin Partners, Commodore Capital, EcoR1 Capital, Fidelity Management and Research Company, Surveyor Capital (a Citadel company), funds and accounts advised by T. Rowe Price Associates, Inc., Woodline Partners, and a large diversified asset manager on the west coast, as well as existing investors including GV (formerly Google Ventures), Invus, Nextech Invest, Omega Funds, Polaris Partners, and Vida Ventures, LLC.
Led by Norbert Bischofberger, Ph.D., President and Chief Executive Officer, Kronos Bio is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.
FinSMEs
24/08/2020